Details for New Drug Application (NDA): 203018
✉ Email this page to a colleague
The generic ingredient in HYDROCHLOROTHIAZIDE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for 203018
Tradename: | HYDROCHLOROTHIAZIDE |
Applicant: | Sciegen Pharms Inc |
Ingredient: | hydrochlorothiazide |
Patents: | 0 |
Pharmacology for NDA: 203018
Physiological Effect | Increased Diuresis |
Medical Subject Heading (MeSH) Categories for 203018
Suppliers and Packaging for NDA: 203018
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 203018 | ANDA | ScieGen Pharmaceuticals, Inc. | 50228-111 | 50228-111-10 | 1000 TABLET in 1 BOTTLE (50228-111-10) |
HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 203018 | ANDA | ScieGen Pharmaceuticals, Inc. | 50228-111 | 50228-111-30 | 30 TABLET in 1 BOTTLE (50228-111-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
Approval Date: | Jul 23, 2014 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
Approval Date: | Jul 23, 2014 | TE: | AB | RLD: | No |
Complete Access Available with Subscription